Related Experiment Video
Updated: Feb 26, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in
Li Peng1, Jun Liu1, Liuan Qin1
1Department of Cardiology, Chinese PLA General Hospital, Beijing, China.
Background:
Both platelet-derived microRNAs and the genotype of CYP2C19*2 were implicated for the variability of clopidogrel antiplatelet responsiveness. However, their interaction on the antiplatelet responsiveness of clopidogrel in patients with acute coronary syndrome (ACS) remains unknown.
Methods:
Consecutive clopidogrel-treated patients with ACS were recruited, with their antiplatelet responsiveness evaluated by the relative platelet inhibition (RI), as measured by light transmittance aggregometry (LTA) at baseline and 5days' after the maintenance treatment of clopidogrel. Extreme cases were selected according to the octiles of RI value. Expression of the microRNAs targeting the mRNAs of P2RY12 was analyzed in the platelet of the extreme cases. Genotyping of CYP2C19*2 was performed for each extreme case.
Results:
Among the included 272 ACS patients, 21 cases were screened as the extremely high-responders with RI>84%, and 18 as the extremely low-responders with RI<10%. Bioinformatics tools predicted the candidate microRNAs of miR-223, miR-221, and miR-21 could bind directly to the mRNA of P2RY12. Compared with the extremely low-responders, the expression of miR-223, miR-221, and miR-21 was significantly higher in the extremely high-responders (miR-223: 7.18±2.95 vs. 0.99±0.64, p=0.022; miR-221: 3.60±2.54 vs. 1.14±0.81, p=0.004; miR-21: 4.36±3.33 vs. 2.31±1.69, p=0.01). ROC curve showed ideal discriminatory power of the platelet-derived miRNAs for the prediction of clopidogrel antiplatelet responsiveness (c-index=0.70 for miR-223; c-index=0.76 for miR-221; c-index=0.79 for miR-21). After stratified by the carrier status of CYP2C19*2, the association between platelet-derived miRNAs and clopidogrel antiplatelet responsiveness could be found only in CYP2C19*2 carriers, but not in non-carriers.
Conclusions:
Platelet-derived miRNAs (miR-223, miR-221 and miR-21) are independently associated with clopidogrel antiplatelet responsiveness in ACS patients. However, the association could be influenced by the interaction with CYP2C19*2 genotype.
Insights
Platelet microRNAs (miR-223, miR-221, miR-21) are linked to clopidogrel response in acute coronary syndrome (ACS) patients. This association is influenced by the CYP2C19*2 genotype, impacting antiplatelet therapy effectiveness.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Molecular Biology
Background:
- Clopidogrel responsiveness varies significantly among patients with acute coronary syndrome (ACS).
- Platelet microRNAs and CYP2C19*2 genotype are known factors influencing clopidogrel efficacy.
- The interaction between these factors and clopidogrel response in ACS remains unclear.
Purpose of the Study:
- To investigate the relationship between platelet-derived microRNAs (miRNAs) and clopidogrel antiplatelet responsiveness in ACS patients.
- To explore the potential interaction between specific microRNAs and the CYP2C19*2 genotype in modulating clopidogrel efficacy.
Main Methods:
- Recruited clopidogrel-treated ACS patients, assessing antiplatelet responsiveness via light transmittance aggregometry (LTA).
- Selected extreme responders and non-responders based on relative platelet inhibition (RI) values.
- Analyzed platelet microRNA expression (miR-223, miR-221, miR-21) and performed CYP2C19*2 genotyping.
Main Results:
- Identified miR-223, miR-221, and miR-21 as potential regulators of P2RY12 mRNA.
- Found significantly higher expression of these microRNAs in extremely high responders compared to low responders.
- Demonstrated that the association between platelet microRNAs and clopidogrel responsiveness was significant only in CYP2C19*2 carriers.
Conclusions:
- Platelet-derived miR-223, miR-221, and miR-21 are independently associated with clopidogrel antiplatelet responsiveness in ACS.
- The interaction with the CYP2C19*2 genotype significantly influences this association, highlighting its importance in personalized antiplatelet therapy.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pharmacogenomics: Identification of New Drug Targets
01:27Pharmacogenetics of Drug Metabolism: Overview
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase